AbbVie Assigns $9.1 Billion Of Its $10.6 Billion Apogee Price To Unapproved Drugs
AbbVie's accounting for the Apogee deal is preliminary, with $2.284 billion of goodwill and a $1.661 billion deferred tax liability.
AbbVie, the biopharmaceutical company behind Skyrizi, Rinvoq and Botox, booked $9.1 billion of its Apogee Therapeutics purchase as in-process research and development, meaning drugs that have not yet won regulatory approval, according to its 10-Q filed Tuesday. The company calls the allocation preliminary.
Where the $10.6 billion went
AbbVie completed the Apogee purchase on September 3, paying $135.11 per share in cash. The fair value of the consideration was $10.6 billion, or $10.5 billion net of cash acquired. The prior quarterly report had described the pending deal as worth about $10.9 billion.
Beyond the $9.1 billion of unapproved-drug assets, AbbVie recorded $2.284 billion of goodwill. A $1.661 billion deferred tax liability brings identifiable net assets to $8.311 billion.
Settling the final valuation may shift intangible assets, goodwill and income taxes. That work must be done within a year of the acquisition date.
AbbVie inherited Apogee's zumilokibart funding deal, now a financing liability of $523 million, $300 million of it current debt. AbbVie recorded a matching $300 million of future funding payments in other assets.
An immunology bet as Humira fades
Apogee's pipeline centers on zumilokibart, a late-stage antibody targeting IL-13 for atopic dermatitis, and APG273, a combination targeting IL-13 and TSLP for asthma. AbbVie says the goodwill reflects expected synergies, including expanding its immunology pipeline.
Immunology is where AbbVie's growth sits. Skyrizi revenue rose 25% in the first nine months of 2026, while Humira fell 36% on a constant-currency basis. Apogee's results since the closing were insignificant, the filing says.
Apogee employee awards cost another $318 million in cash-settled expense after closing, booked in the third quarter. It funded the deal with $10.0 billion of senior notes issued in August, after which it terminated a $10.0 billion term loan facility.
A $27.3 billion liability and a Botox ruling
AbbVie's contingent consideration liabilities, which are payments owed to sellers of earlier acquisitions, stood at $27.3 billion at September 30, up from $25.4 billion at December 31, 2025. Fair-value charges of $4.7 billion this year drove the increase. The balance sheet also shows a stockholders' deficit of $4.583 billion.
A court ruling on October 29 blocked Botox's Medicare price negotiation. The government can appeal.
AbbVie has until one year after the September 3 closing to finalize the Apogee allocation, and the government may still appeal the Botox ruling.
Sources
- 10-Q Filing — AbbVie (ABBV) — SEC EDGAR
- 10-Q Filing — AbbVie (ABBV), Q2 FY2026 filed 2026-08-03 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, abbv-20260930xexhibit991.htm) — AbbVie, filed 2026-10-30 — SEC EDGAR
- 8-K Filing — AbbVie, filed 2026-11-02 (Items 5.02) — SEC EDGAR
